2. Search Result
Search Result
Results for "

HLA-A2

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

12

Peptides

Cat. No. Product Name Target Research Area
  • HY-P1700
    BCMA72-80

    		Peptides Cancer
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .
  • HY-P1881
    HPV16-E711-20 epitope

    		HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
  • HY-P2524
    MAGE-3 (271-279)

    		Peptides Cancer
    MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .
  • HY-106187
    MART-1 (27-35) (human)

    		Peptides Inflammation/Immunology
    MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .
  • HY-P1778
    HPV16 E7 (86-93)

    		HPV Infection
    HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas [2].
  • HY-P1778A
    HPV16 E7 (86-93) (TFA)

    		HPV Infection
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas [2].
  • HY-P4032
    HCV Peptide (35-44)

    		HCV Inflammation/Immunology
    HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
  • HY-P5294
    YLLEMLWRL

    		Peptides Cancer
    YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .
  • HY-P1919
    [Asp371]-Tyrosinase (369-377), human

    		Peptides Cancer
    Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy [2].
  • HY-P1914
    NY-BR-1 p904 (A2)

    		Peptides Cancer
    NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1 .
  • HY-P1855
    HER2/neu (654-662) GP2

    		EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers [2].
  • HY-P3248
    J5 peptide

    Myelin basic protein (85-99) antagonist

    		 Biochemical Assay Reagents Inflammation/Immunology
    J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP85-99 to HLA-DR2. J5 peptide alleviates PLP139-151/MBP85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: